JY
KURA icon

Jeff Yass’s Kura Oncology KURA Stock Holding History

Jeff Yass’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Sell
22,000
-117,800
-84% -$1.11M ﹤0.01% 11549
2026
Q1 		$1.14M Buy
139,800
+76,300
+120% +$655K ﹤0.01% 7550
2025
Q4 		$660K Sell
63,500
-100,800
-61% -$1.06M ﹤0.01% 8171
2025
Q3 		$1.45M Buy
+164,300
New +$1.17M ﹤0.01% 6467
2025
Q2 		– Sell
-21,300
Closed -$141K – 13244
2025
Q1 		$141K Sell
21,300
-48,000
-69% -$374K ﹤0.01% 11281
2024
Q4 		$604K Buy
69,300
+47,000
+211% +$676K ﹤0.01% 8214
2024
Q3 		$436K Sell
22,300
-10,000
-31% -$203K ﹤0.01% 8796
2024
Q2 		$665K Sell
32,300
-43,200
-57% -$888K ﹤0.01% 7557
2024
Q1 		$1.61M Buy
75,500
+54,200
+254% +$1.05M ﹤0.01% 5832
2023
Q4 		$306K Sell
21,300
-66,200
-76% -$651K ﹤0.01% 9796
2023
Q3 		$798K Sell
87,500
-30,500
-26% -$310K ﹤0.01% 7152
2023
Q2 		$1.25M Buy
+118,000
New +$1.4M ﹤0.01% 6182
2023
Q1 		– Sell
-40,700
Closed -$505K – 13080
2022
Q4 		$505K Buy
40,700
+21,000
+107% +$305K ﹤0.01% 7847
2022
Q3 		$269K Buy
19,700
+6,400
+48% +$98.7K ﹤0.01% 10071
2022
Q2 		$244K Sell
13,300
-300
-2% -$4.32K ﹤0.01% 10126
2022
Q1 		$219K Sell
13,600
-152,800
-92% -$2.21M ﹤0.01% 11020
2021
Q4 		$2.33M Buy
166,400
+148,900
+851% +$2.41M ﹤0.01% 5144
2021
Q3 		$328K Buy
+17,500
New +$330K ﹤0.01% 10392
2021
Q1 		– Sell
-111,900
Closed -$3.65M – 12558
2020
Q4 		$3.65M Buy
111,900
+76,700
+218% +$2.7M ﹤0.01% 3971
2020
Q3 		$1.08M Buy
35,200
+10,600
+43% +$234K ﹤0.01% 5926
2020
Q2 		$401K Buy
+24,600
New +$355K ﹤0.01% 7814
2018
Q4 		– Sell
-10,200
Closed -$179K – 9492
2018
Q3 		$179K Sell
10,200
-107,000
-91% -$2.05M ﹤0.01% 8305
2018
Q2 		$2.13M Buy
+117,200
New +$1.99M ﹤0.01% 3905

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Jeff Yass's KURA Position: Q2 2026 in Review

Jeff Yass reduced its Kura Oncology (KURA) stake by 84% in Q2 2026, selling an estimated $783K and leaving 15,576 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #12095.

Jeff Yass first reported a position in KURA in Q1 2017 and has held it in 28 quarters since. The position peaked at $12.7M in Q1 2024. 219 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Jeff Yass held 15,576 shares of Kura Oncology worth $171K as of Q2 2026.
  • Jeff Yass sold 83,016 Kura Oncology shares in Q2 2026, an estimated $783K.
  • Kura Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12095 holding.
  • Jeff Yass first reported a position in Kura Oncology in Q1 2017 and has held it in 28 quarters since.
  • Jeff Yass's Kura Oncology position peaked at $12.7M in Q1 2024.
  • 219 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.